Qyuns Therapeutics' Plaque Psoriasis Drug Gets Registration Certificate from Chinese Regulator

MT Newswires Live11-05

Qyuns Therapeutics (HKG:2509) affiliate Hangzhou Zhongmei Huadong Pharmaceutical has received a drug registration certificate for the ustekinumab injection approved by China's National Medical Products Administration, a Tuesday bourse filing said.

The drug has been approved for the treatment of moderate-to-severe plaque psoriasis in adults.

The ustekinumab injection was initially developed independently by Qyuns Therapeutics. The company later reached a collaboration agreement with Hangzhou Zhongmei Huadong Pharmaceutical to jointly advance its phase III clinical trial related to the drug.

Shares of the biotechnology company closed nearly 2% higher on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481575945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481575945","market":"hk","top_or_hot":-1,"title":"Qyuns Therapeutics' Plaque Psoriasis Drug Gets Registration Certificate from Chinese Regulator","media":"MT Newswires Live","content":"<html><body><p> Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2509) affiliate Hangzhou Zhongmei Huadong Pharmaceutical has received a drug registration certificate for the ustekinumab injection approved by China's National Medical Products Administration, a Tuesday bourse filing said.</p><p>The drug has been approved for the treatment of moderate-to-severe plaque psoriasis in adults.</p><p>The ustekinumab injection was initially developed independently by Qyuns Therapeutics. The company later reached a collaboration agreement with Hangzhou Zhongmei Huadong Pharmaceutical to jointly advance its phase III clinical trial related to the drug.</p><p>Shares of the biotechnology company closed nearly 2% higher on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics' Plaque Psoriasis Drug Gets Registration Certificate from Chinese Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics' Plaque Psoriasis Drug Gets Registration Certificate from Chinese Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 18:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Qyuns Therapeutics (HKG:2509) affiliate Hangzhou Zhongmei Huadong Pharmaceutical has received a drug registration certificate for the ustekinumab injection approved by China's National Medical ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481575945","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481575945","pubTimestamp":1730803681,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Qyuns Therapeutics  affiliate Hangzhou Zhongmei Huadong Pharmaceutical has received a drug registration certificate for the ustekinumab injection approved by China's National Medical Products Administration, a Tuesday bourse filing said.The drug has been approved for the treatment of moderate-to-severe plaque psoriasis in adults.The ustekinumab injection was initially developed independently by Qyuns Therapeutics. The company later reached a collaboration agreement with Hangzhou Zhongmei Huadong Pharmaceutical to jointly advance its phase III clinical trial related to the drug.Shares of the biotechnology company closed nearly 2% higher on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK4139":"生物科技","LENZ":"Therapeutics","BK1161":"生物科技"},"translate_title":"Qyuns Therapeutics的斑块型银屑病药物获得中国监管机构的注册证书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"02509":0.9},"content_text":"Qyuns Therapeutics (HKG:2509) affiliate Hangzhou Zhongmei Huadong Pharmaceutical has received a drug registration certificate for the ustekinumab injection approved by China's National Medical Products Administration, a Tuesday bourse filing said.The drug has been approved for the treatment of moderate-to-severe plaque psoriasis in adults.The ustekinumab injection was initially developed independently by Qyuns Therapeutics. The company later reached a collaboration agreement with Hangzhou Zhongmei Huadong Pharmaceutical to jointly advance its phase III clinical trial related to the drug.Shares of the biotechnology company closed nearly 2% higher on Tuesday.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481575945"}